SCHEMBL3012030

SCHEMBL3012030

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)cc(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.48
MAPT P10636 2/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
POLB P06746 2/20 0.44
KMT2A Q03164 2/20 0.42
THRB P10828 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 1/20 0.42
IDO1 P14902 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LPAR1 Q92633 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
LMNA P02545 2/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TSHR P16473 1/20 0.40
F2RL3 Q96RI0 2/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016522 0.93 POLB (0.48) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3013624 0.92 HSD17B10 (0.50) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3015522 0.92 MAPT (0.54) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3004407 0.91 MAPT (0.51) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3016965 0.89 VCAM1 (0.49) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3012681 0.89 SMN1; SMN2 (0.46) HSD17B10MAPTUSP2RECQLKMT2A
SCHEMBL3018680 0.89 MAPT (0.49) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3009813 0.89 TSHR (0.51) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3006007 0.89 MAPT (0.45) HSD17B10MAPTUSP2RECQLPOLB
SCHEMBL3023042 0.89 USP2 (0.52) HSD17B10MAPTUSP2RECQLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD17B10 2553/4885MAPT 18/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.